81.17
0.39 (0.48%)
| Penutupan Terdahulu | 80.78 |
| Buka | 79.41 |
| Jumlah Dagangan | 1,083,041 |
| Purata Dagangan (3B) | 810,707 |
| Modal Pasaran | 4,391,808,512 |
| Harga / Jualan (P/S) | 21.65 |
| Harga / Buku (P/B) | 18.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -50.07% |
| Margin Operasi (TTM) | -38.42% |
| EPS Cair (TTM) | -1.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 66.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 34.26% |
| Nisbah Semasa (MRQ) | 6.02 |
| Aliran Tunai Operasi (OCF TTM) | -91.61 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -82.85 M |
| Pulangan Atas Aset (ROA TTM) | -16.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | PROCEPT BioRobotics Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.63 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 86.70% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 112.00 (Wells Fargo, 37.98%) | Beli |
| Median | 105.00 (29.36%) | |
| Rendah | 75.00 (Piper Sandler, -7.60%) | Beli |
| Purata | 98.40 (21.23%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 89.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 03 Dec 2024 | 112.00 (37.98%) | Beli | 96.48 |
| Morgan Stanley | 02 Dec 2024 | 105.00 (29.36%) | Beli | 96.11 |
| Jefferies | 14 Nov 2024 | 95.00 (17.04%) | Pegang | 85.91 |
| Truist Securities | 30 Oct 2024 | 105.00 (29.36%) | Beli | 93.03 |
| Piper Sandler | 08 Oct 2024 | 75.00 (-7.60%) | Beli | 74.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2024 | Pengumuman | PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 |
| 29 Oct 2024 | Pengumuman | PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock |
| 28 Oct 2024 | Pengumuman | PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance |
| 28 Oct 2024 | Pengumuman | Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner |
| 28 Oct 2024 | Pengumuman | PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock |
| 09 Oct 2024 | Pengumuman | PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 |
| 07 Oct 2024 | Pengumuman | PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |